Inhibitor of cyclooxygenase (COX); Pan partial agonist of PPARγ, PPARα and PPARβ/δ

Inhibitor of viral replication, especially useful in the treatment of the Herpes family of viruses which includes Herpes Simplex 1 and 2 , EBV , CMV and Varicella.

Natural Potent Marine-Derived Elastase Inhibitor

Nove fluorescent probe for highly sensitive monitoring drug induced lysosomal pH value changes, exhibiting good biological compatibility, low cytotoxicity and high resistance to photobleaching

Novel F1F0-ATPase modulator, significantly decreasing M2 glutamate and increasing M4 glutamate

Novel inhibitor of the type I transforming growth factor beta receptor (TβRI)

Prodrug of LY354740, highly selective and potent agonist of group II mGlu receptors (mGluR2)

Novel competitive GLUK5 receptor antagonist

Novel potent and selective dual PPARalpha/gamma agonist

Selective mGlu1 receptor antagonist

AMPA receptor potentiator

Orally active ghrelin agonist, bindjng with high affinity to and being a potent activator of the growth hormone secretagogue receptor 1a (GHS-R1a) receptor

Allosteric modulator of AMPA receptors

AMPA receptor potentiator

Selective GluR5 kainate receptor antagonist

Potent GluR5 kainate receptor agonist

Potent and selective inhibitor of PKCβI and PKCβII

Novel highly potent and selective agonist of metabotropic glutamate (mGlu) receptors 2 and 3

Selective cell permeable phosphatidylinositol 3-kinase (PI3K) inhibitor

Novel, potent, and systemically bioavailable mGlu2/3 receptor agonist, exhibiting both antipsychotic and analgesic properties in vivo

Orally active cell-permeable inhibitor of human

Potent 5-HT3 serotonin receptor antagonist

Selective negative allosteric modulator of mGlu3

Potent antioxidant, being cytoprotective in models of focal and global cerebral ischemia

Novel mGlu2/3 receptor agonist; Prodrug of LY-404039

Novel glucokinase activator (GKA)

Novel, potent, orally-bioavailable kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders

Novel LRRK2 kinase inhibitor against the wild-type and G2019S mutant LRRK2 kinase being 1526.00 ± 0.87 nM, 1165.00 ± 1.18 nM, respectively

Novel LRRK2 kinase inhibitor against the wild-type and G2019S mutant LRRK2 kinase being 424.40 ± 1.31 nM, 378.80 ± 1.20 nM, respectively

Novel potent HIF-1 inhibitor, also downregulating the protein level of HIF-1alpha, which depended on von Hippel-Lindau for proteasome degradation, showing in vivo anticancer efficacy by decreasing the HIF-1alpha expression in nude mice bearing MX-1 tumor